首页> 美国卫生研究院文献>Case Reports in Ophthalmological Medicine >Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane)
【2h】

Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane)

机译:曲安奈德丙酮的次特农注射液对继发于纳米粒子白蛋白结合的紫杉醇(阿贝沙星)的囊状黄斑水肿的作用有限。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. To report the first case of cystoid macular edema (CME) induced by nanoparticle albumin-bound- (nab-) paclitaxel treated with sub-Tenon injections of triamcinolone acetonide (STTA) with detailed long-term follow-up. Case. A 39-year-old Japanese woman with breast cancer presents with decreased vision in both eyes while receiving nab-paclitaxel. Two STTA treatments were administered for persistent CME in her right eye. Central retinal thickness (CRT) of the treated eye decreased after the first STTA, but there was no change after the second STTA. CRT of the other eye and bilateral visual acuity (VA) showed no change after each treatment. However, this patient experienced gradual recovery of visual function after nab-paclitaxel treatment was completed, 3 months after the second STTA. Improvements in VA and CRT did not overlap in time. Moreover, there was a big improvement time lag in VA between the eyes. Conclusion. Cessation of nab-paclitaxel could lead to resolution of CME more than STTA, although STTA had some effect. Since nab-paclitaxel has been recently approved for treating more types of malignancies, the number of the patients with this CME is expected to increase in the near future. Patients and physicians should understand this side effect and prepare for other treatment options.
机译:目的。报告第一例由纳米粒子白蛋白结合的(nab-)紫杉醇诱导的囊性黄斑水肿(CME)的治疗,特纳注射曲安奈德(STTA)进行亚特农注射,并进行详细的长期随访。案件。一名39岁的日本乳腺癌女性患者在接受nab-紫杉醇治疗后双眼视力下降。对于她的右眼持续性CME,进行了两种STTA治疗。第一次STTA治疗后,治疗眼的中央视网膜厚度(CRT)降低,但在第二次STTA治疗后,视网膜中央厚度没有变化。每次治疗后,另一只眼的CRT和双侧视力(VA)均无变化。然而,该患者在第二次STTA结束3个月后,完成nab-紫杉醇治疗后视觉功能逐渐恢复。 VA和CRT的改善在时间上没有重叠。而且,两眼之间的VA有很大的改善时间差。结论。尽管STTA发挥了一定作用,但停止nab-紫杉醇可能导致CME的溶解度高于STTA。由于nab-紫杉醇最近已被批准用于治疗更多类型的恶性肿瘤,因此预期这种CME的患者人数将在不久的将来增加。患者和医师应了解这种副作用并准备其他治疗方案。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号